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Abstract
Background Treatment of severe sepsis is expensive, often encompassing a number of discretionary
modalities. The objective of the present study was to assess intercenter variation in resource and
therapeutic modality use in patients with severe sepsis.
Methods We conducted a prospective cohort study of 1028 adult admissions with severe sepsis from
a stratified random sample of patients admitted to eight academic tertiary care centers. The main
outcome measures were length of stay (LOS; total LOS and LOS after onset of severe sepsis) and
total hospital charges.
Results The adjusted mean total hospital charges varied from $69429 to US$237898 across
centers, whereas the adjusted LOS after onset varied from 15.9 days to 24.2 days per admission.
Treatments used frequently after the first onset of sepsis among patients with severe sepsis were
pulmonary artery catheters (19.4%), ventilator support (21.8%), pressor support (45.8%) and albumin
infusion (14.4%). Pulmonary artery catheter use, ventilator support and albumin infusion had moderate
variation profiles, varying 3.2-fold to 4.9-fold, whereas the rate of pressor support varied only 1.92-fold
across centers. Even after adjusting for age, sex, Charlson comorbidity score, discharge diagnosis-
relative group weight, organ dysfunction and service at onset, the odds for using these therapeutic
modalities still varied significantly across centers. Failure to start antibiotics within 24 hours was
strongly correlated with a higher probability of 28-day mortality (r2=0.72).
Conclusion These data demonstrate moderate but significant variation in resource use and use of
technologies in treatment of severe sepsis among academic centers. Delay in antibiotic therapy was
associated with worse outcome at the center level.
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Introduction
Each year approximately 750000 patients in the USA suffer
from sepsis. Treatment for this disease costs $16.7 billion
annually [1]. Despite advances in supportive intensive care
and use of appropriate antibiotics, the mortality associated
with sepsis remains high, especially among those who
develop hemodynamic shock [2–4]. Such patients frequently
progress to multiple organ dysfunction syndrome, which
results in a much higher mortality rate than among patients
who do not develop such complications [3,5–7]. This life-
threatening syndrome is largely attributed to the cardiovascu-
lar abnormalities associated with septic shock, requiring
supportive therapy (e.g. mechanical ventilation, fluid resusci-
tation, and vasopressors) with volume loading, oxygen deliv-
ery, and regional perfusion [8]. However, there are still many
controversies regarding choice of fluids [9–12], vasopressors
[13–15], hemodynamic end-points for resuscitation [16–20],
and monitoring techniques. Findings from a national survey of
intensive care unit (ICU) utilization showed differences in
types of procedures performed between unit types and hos-
pital sizes [21].
The goals of the present study were to examine systematically
the variations in overall resource use, therapeutic modality
use, and outcome in patients with severe sepsis across acad-
emic medical centers, and to evaluate relationships between
therapeutic modality use and variation in resource use.
Methods
Patient population
All participating centers were members of the Academic
Medical Center Consortium, which sponsored the study. All
eight centers were large tertiary care academic medical
centers with approximately 18800–43700 admissions annu-
ally [22]. Patient enrollment occurred between January 1993
and April 1994.
Patients surveyed represented a stratified random sample of
patients in ICUs and outside ICUs for whom blood cultures
were either positive or negative, as previously described [22].
Among non-ICU patients with blood cultures that were nega-
tive at 48 hours, sampling at all centers was fixed at 10%.
Among ICU patients and patients with a blood culture posi-
tive for a pathogen within 48 hours, the fraction of patients
sampled was established at each center and varied from
30% to 60%. In addition, all patients who died in an emer-
gency department or an ICU and all patients who received a
novel therapy for sepsis syndrome were surveyed. The ICUs
involved included both open and closed units.
Although previous reports included 1342 episodes of sepsis
among 1166 unique patients with 1190 hospital admissions
[22,23], the results presented here from the same database
were based on the 1011 (87%) patients, representing 1028
(86%) admissions with 1173 (87%) episodes of sepsis syn-
drome, for whom billing information was available. When
patients had more than one episode in an admission, only the
first episode in that admission was evaluated.
Definitions
Sepsis syndrome was defined as described by Sands and
coworkers [22], using a modification of the criteria developed
by Bone [24], and involved assessment of the presence of
both screening criteria and confirmatory criteria for sepsis
syndrome. Either of the following were required for a patient
to satisfy the screening criteria: all four of temperature greater
than 38.3°C or less than 35.6°C rectally, respirations greater
than 20/min or mechanical ventilation, heart rate greater than
90 beats/min, and clinical evidence of infection; or one or
more blood cultures positive for a pathogen at 48 hours fol-
lowing admission. Presence of any of the following seven fea-
tures, without an alternative cause, was required for
satisfaction of the confirmatory criteria: ratio of partial arterial
oxygen tension to inspired fractional oxygen below 280 (intu-
bated) or 40% face mask in use (nonintubated); arterial pH
below 7.30; urine output below 30ml/h; systolic blood pres-
sure below 90mmHg or a fall in systolic blood pressure by
more than 40mmHg sustained for 2 hours despite fluid chal-
lenge; systemic vascular resistance below 800 dynes·s/cm5;
prothrombin time or partial thromboplastin time greater than
normal or platelets below 100.0×109/l or platelets
decreased to less than 50% or most recent measurement
before current day; and documentation of deterioration in
mental status within 24 hours. In addition, all patients who
received a form of novel therapy for sepsis syndrome were
enrolled in the sepsis syndrome group. Because all patients
with sepsis syndrome also meet the criteria for ‘severe
sepsis’ (the term that is most popular now), below we use the
term ‘severe sepsis’.
Acute respiratory distress syndrome (ARDS) was defined as
partial arterial oxygen tension below 50mmHg despite frac-
tional inspired oxygen in excess of 50%, and bilateral pul-
monary infiltrates without signs of heart failure. Disseminated
intravascular coagulation (DIC) was defined as a positive
D-dimer or elevated fibrin degradation products plus a falling
platelet count of 25% of less of baseline, and elevation of
either prothrombin time or partial prothrombin time, or clinical
evidence of bleeding. Central nervous system (CNS) dys-
function was defined as a Glasgow Coma Scale score below
15 in patients with normal results at baseline neurologic
examination, or at least 1 point lower than baseline in patients
with a previously abnormal examination result. Renal failure
was defined as an increase in serum creatinine of at least
2.0mg/dl during the sepsis episode if creatinine was below
1.5mg/dl at baseline, or an absolute increase of 1.0mg/dl or
more if baseline creatinine was at least 1.5. Liver failure was
defined as present if total bilirubin was 2.0mg/dl or greater,
and either the alkaline phosphatase or a transaminase level
was greater than twice normal, in the absence of confounding
disease. Shock (after onset of sepsis) was defined as either
at least 1 hour of decreased systolic blood pressure by atR26
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least 40mmHg, or systolic blood pressure of 90 mmHg or
less after adequate volume replacement, and in the absence
of antihypertensive agents, or continuous infusion of pres-
sors. Uncontrolled hemorrhage was defined as active and
live-threatening bleeding, requiring transfusions of more than
4 units within 24 hours of onset of sepsis. Moderate or severe
liver disease was defined as cirrhosis with portal hyperten-
sion, or hepatic failure with coma or encephalopathy within
the preceding 6 months.
Data collection
Surveyors recorded the presence of all screening criteria for
every day that a patient was a valid member of the surveil-
lance group. If screening criteria were met, then the patient
was enrolled as a case and detailed information, including
demographic, historical, clinical and laboratory data, were
abstracted from the medical record into a standardized data
collection form for which all variables and criteria were
defined. Additional data, including information on antibiotic
use, treatment modalities (pulmonary artery catheter [PAC]
use, ventilator support, pressor support, albumin infusion,
hetastarch, and dextran), complications (ARDS, renal failure,
liver failure, DIC, and shock), and associated outcomes, were
abstracted 28 days after the first onset of severe sepsis or at
the time of death or hospital discharge, whichever came first.
Hospital length of stay (LOS) before and after the onset of
severe sepsis and total hospital charge were obtained from
the unified Academic Medical Center Consortium hospital
billing database.
We calculated the patient’s Charlson comorbidity score [25];
a higher score reflects greater comorbidity. We also obtained
information on discharge diagnosis-relative groups (DRGs)
and DRG weight. The current generation of DRGs was origi-
nally based on ICD-9-CM and takes into consideration opera-
tions, complications, and comorbidities. Each DRG was
preassigned an average LOS and reimbursement rate by the
US Health Care Financing Administration. The higher the
DRG weight, the higher the level of reimbursement.
Analyses
Because the sampling fractions from different strata varied
[22], individual cases carried different weight [23] and all cal-
culations, including means and proportions, were performed
using appropriate case weights.
We compared the proportion of sepsis patients receiving
each intervention therapy and then the proportion with com-
plications among eight academic centers, using weighted χ2
statistics. We also calculated the ratio of the highest to
lowest proportion for each intervention and complication.
Multivariate comparisons were made using generalized linear
modeling, with post-onset LOS and hospital charges as
dependent variables and study center (coded as dummy vari-
ables) as the main covariate, adjusting for age, sex, Charlson
comorbidity score, discharge DRG weight, organ dysfunction
(ARDS, uncontrolled hemorrhage, moderate or severe liver
disease, or acute renal failure), and service (surgical versus
medical) at onset of sepsis. The same adjustment of variables
was applied in logistic regression models to compare the like-
lihood that a sepsis patient at a particular center received an
intervention and experienced a complication, arbitrarily
choosing center #1 as the reference center. Because
patients within the same center could share some common
characteristics, generalized estimating equation regression
models were used to perform the analyses on the compar-
isons of resource use between patients with and without use
of modalities. The r2 value was calculated for each model. All
analyses were performed using the SAS statistical package
(SAS Institute, Inc., Cary, NC, USA) [26].
Results
The study cohort included 1028 admissions with severe
sepsis distributed across the eight participating centers,
ranging from 91 to 261 admissions with severe sepsis
episodes per study center (Table 1). The study patients were
predominantly males in six of the eight centers, and the mean
ages ranged from 55 to 60 years across the centers. The
mean Charlson score and discharge DRG weight were 2.6
(range 2.3–2.9) and 4.8 (range 3.7–6.0), respectively. Almost
half of the patients with severe sepsis underwent surgery
during their hospital stay. The percentage undergoing organ
transplantation varied from 0.4% to 11.3% across centers.
The proportion of patients who had an infectious etiology for
their primary discharge DRG varied from 6.1% to 23.5%
among the participating centers.
Variation in resource use
There was significant variation in mean total charges among
admissions with severe sepsis among the study centers,
varying from $65162 (median $42802) to $244293
(median $181758; Table 2). The mean post-onset LOS
varied from 16.1 days to 24.8 days (median range
9–16 days) among centers. Other measures of resource uti-
lization including total LOS and LOS in the ICU were also
significantly different across centers, with means of
22.7–36.9 days and 5.0–17.8 days, respectively. After
adjusting for age, sex, Charlson comorbidity score, discharge
DRG weight, organ dysfunction, and service at onset of
sepsis, the variations in mean total charges and post-onset
LOS remained significant, ranging from $69429±$9562 to
$237898±$12129, and from 15.9±2.0 days to
24.2±1.8 days, respectively (Table 3).
Variation in therapeutic modality use
Interventions used frequently after the onset of severe sepsis
included PACs (19.4%), ventilator support (21.8%), pressor
support (45.8%), and albumin infusion (14.4%; Table 4).
Although there were variations across medical centers for
each therapeutic modality, variation profiles differed substan-
tially among the modalities. Modalities with moderate variation
profiles among the eight participating centers included PACsR27
(varied 4.0-fold, 95% confidence interval [CI] of 2.6-fold to
6.4-fold; range 8.7% to 35.1%), ventilator support (varied
3.2-fold, 95% CI 2.1-fold to 4.9-fold; range 11.5% to 36.4%),
and albumin infusion within 24 hours after sepsis onset
(varied 4.9-fold, 95% CI 2.2-fold to 10.9-fold; range 6.0% to
29.1%). In contrast, use of pressor support varied only 1.9-
fold (95% CI 1.4-fold to 2.6-fold) across centers, ranging
from 31.4% to 60.4%, and antibiotics given within 24 hours
after onset had the least variation, of 1.1-fold (95% CI
1.0-fold to 1.1-fold) and ranging from 87.0% to 98.5%. Use
of hetastarch and use of dextran within 24 hours after onset
in sepsis patients were the least common therapeutic modali-
ties among the eight centers, with ranges of 0–6.8% and
0–6.2%, respectively. Of patients receiving pressors within
24 hours after sepsis onset, 28.3% received low-dose
dopamine only (<5µg/kg per min); the proportion varied
7-fold (95% CI 2.4-fold to 20.8-fold) across centers, ranging
from 6.4% in center 5 to 44.8% in center 1 (data not shown).
The results of models adjusting for age, sex, Charlson comor-
bidity score, discharge DRG weight, organ dysfunction, and
service at onset of sepsis are shown in Fig.1. Centers that
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Table 1
Patient characteristics by participating center
Center
C1 C2 C3 C4 C5 C6 C7 C8 All
Admissions with episode 261 (9.3) 143 (5.6) 97 (7.2) 109 (13.2) 104 (6.5) 91 (5.5) 97 (9.3) 126 (9.9) 1028 (8.5)
(% multiple episodes)
Patients (n) 253 142 97 109 100 91 96 123 1011
Episodes (n) 298 156 111 139 113 104 107 145 1173
Age (mean±SD) 55±19 60±20 57±17 56±19 59±20 60±16 60±19 59±20 58±19
Males (%) 58.9 64.6 62.7 46.2 65.1 57.7 41.2 66.4 58.2
On surgical service at 38.8 38.3 41.4 38.0 37.5 32.3 35.8 35.7 37.5
onset (%)
Charlson score 2.3±2.6 2.5±2.9 2.8±2.6 2.8±3.1 2.7±2.8 2.9±2.9 2.9±3.1 2.3±2.3 2.6±2.8
(mean±SD)
Self-pay or Medicaid (%) 10.0 17.4 21.8 20.4 20.0 16.2 10.2 11.9 15.0
In ICU at onset of sepsis (%) 57.0 39.4 62.7 41.0 37.0 62.7 57.1 54.1 50.8
Discharge DRG weight 5.0±6.1 3.9±5.7 5.5±5.6 4.9±6.4 3.7±4.6 4.4±5.1 6.0±8.2 5.4±6.4 4.8±6.1
(mean±SD)
Primary discharge DRG (%)
Surgery 48.3 41.1 56.7 50.7 43.0 39.3 41.6 48.3 46.1
Cancer 7.0 5.5 5.8 1.4 0.8 3.5 9.1 7.4 5.4
Transplant 3.0 1.0 0.4 3.5 1.9 5.2 11.3 2.1 3.3
AIDS 5.9 0 3.4 14.2 7.7 6.0 0 4.9 5.2
Infectious 15.1 23.5 11.1 6.1 19.2 20.9 14.0 21.0 16.6
Other 20.7 28.9 22.6 24.1 27.5 25.1 24.0 16.3 23.4
APACHE III chance of 0.75±0.24 0.73±0.25 0.75±0.20 0.72±0.21 0.71±0.24 0.69±0.23 0.68±0.28 0.63±0.26 0.71±0.24
28-day survival (mean±SD)
Organ dysfunction at onset (%)
ARDS 2.2 7.6 6.5 3.0 7.3 6.2 1.1 9.0 5.0
Uncontrolled hemorrhage 1.0 3.0 4.3 1.4 0.6 1.0 1.1 2.1 1.7
Moderate or severe liver 1.3 5.0 3.4 8.2 4.3 4.1 13.6 2.8 4.8
disease
Acute renal failure 5.1 16.3 12.2 14.8 10.5 11.3 0 11.4 9.8
APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; C, center; DRG, diagnosis-related group;
ICU, intensive care unit; SD, standard deviation.R28
had rates significantly higher than the reference center were
centers 3, 4, 5, 6, and 8 for PAC use; centers 2, 3, 4, 5, and
8 for ventilator support; center 7 for pressor support; and
centers 2, 7, and 8 for albumin infusion. In contrast, signifi-
cantly lower rates for antibiotic use within 24 hours after
onset were identified in centers 3, 4, 5, 6, 7, and 8.
Variation in outcomes
Among all patients with severe sepsis, frequent complications
included shock (45.4%), renal failure (19.7%), CNS dysfunc-
tion (18.9%), liver failure (12.2%), DIC (10.3%), ARDS
(9.1%), and death (30.0%) within 28 days after sepsis onset
(Table 5). There was significant variation in each type of com-
plication across the eight centers, with ranges of
23.9–70.0% for shock, 9.5–35.0% for renal failure,
0.3–37.5% for CNS dysfunction, 4.1–27.9% for liver failure,
5.5–15.0% for DIC, 2.8–21.8% for ARDS, and 19.3–49.1%
for 28-day mortality rate.
Figure2 shows the results of differences in rates of sepsis
complications adjusted for age, sex, Charlson comorbidity
score, discharge DRG weight, organ dysfunction, and service
at onset of sepsis. Analysis of the 28-day in-hospital adjusted
mortality rates revealed 3-fold variability among centers. Com-
pared with the reference center, higher rates were found for
ARDS among one center (C8), for renal failure among five
centers (C3, C4, C5, C7, and C8), for liver failure among one
center (C4), for shock among six centers (C3, C4, C5, C6,
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Table 2
Resource utilization among patients with severe sepsis in eight centers
Site Total charges ($) Total LOS Post-onset LOS LOS in ICU
C1 (n = 261)
Mean ± SD 92,201 ± 120,457 28.0 ± 29.0 19.9 ± 22.6 12.2 ± 22.4
Median (25th, 75th percentile) 68,001 (29,220, 132,236) 21 (11, 35) 14 (8, 25) 7 (2, 18)
C2 (n = 143)
Mean ± SD 67,240 ± 107,234 22.7 ± 30.5 17.1 ± 25.1 5.0 ± 11.8*
Median (25th, 75th percentile) 42,219 (13,733, 84,361) 15 (7, 30) 11 (5, 21) 1 (0, 7)
C3 (n = 97)
Mean ± SD 244,293 ± 217,219* 30.0 ± 24.3 21.4 ± 23.3 17.8 ± 21.1
Median (25th, 75th percentile) 181,758 (90,044, 374,095) 28 (10, 42) 17 (4, 32) 11 (3, 33)
C4 (n = 109)
Mean ± SD 65,162 ± 84,024 30.6 ± 30.0 21.0 ± 24.0 14.1 ± 24.9
Median (25th, 75th percentile) 42,802 (24,415, 100,715) 24 (14, 39) 16 (9, 25) 8 (3, 22)
C5 (n = 104)
Mean ± SD 72,970 ± 129,237 24.4 ± 33.6 19.7 ± 31.6 9.1 ± 20.7
Median (25th, 75th percentile) 44,846 (22,095, 112,674) 17.5 (9, 36) 13.5 (5, 25.5) 4 (0, 18)
C6 (n = 91)
Mean ± SD 88,638 ± 93,098 24.4 ± 20.7 17.1 ± 17.6 12.1 ± 15.0
Median (25th, 75th percentile) 61,982 (26,340, 128,770) 19 (11, 37) 13 (5, 26) 9 (2, 21)
C7 (n = 97)
Mean ± SD 194,986 ± 261,132* 25.4 ± 34.3 16.1 ± 21.2 12.6 ± 18.0
Median (25th, 75th percentile) 92,714 (34 143, 209,007) 14 (7, 28) 9 (4, 18) 6 (0, 13)
C8 (n = 126)
Mean ± SD 86,478 ± 89,866 36.9 ± 36.4* 24.8 ± 29.4* 13.0 ± 20.9
Median (25th, 75th percentile) 61,946 (25,698, 113,446) 22.5 (13, 49) 16 (7, 31) 7 (1, 20)
All (n = 1028)
Mean ± SD 103,529 ± 153,692 27.7 ± 30.6 19.6 ± 24.7 11.5 ± 20.3
Median (25th, 75th percentile) 63,496 (26,366, 137,046) 20 (10, 37) 13 (6, 25) 6 (1, 18)
C, center; ICU, intensive care unit; length of stay. *P<0.05, versus C1.R29
C7, and C8), and for 28-day mortality among four centers
(C3, C6, C7, and C8).
Also, a significant inverse correlation was seen between
antibiotic use within 24 hours after onset of episode and the
28-day mortality rates (r2=0.72; P=0.01; Fig.3). This corre-
lation remained significant even after excluding patients with
‘do not resuscitate’ orders (r2=0.63;  P=0.02). Significant
associations were not found between 28-day mortality and
the use of other modalities across the eight centers (data not
shown).
Relation between resource use and modalities
Comparisons of resource use among patients treated with
specific modalities and those who were not showed that
administration of antibiotics within 24 hours after sepsis
onset had no impact on any of the LOS categories, but was
associated with total and daily hospital charges (Table 6).
Use of other modalities (including albumin infusion) was
associated with increased resource use for daily hospital
charges. Total hospital charges and LOS in the ICU were sig-
nificantly higher among patients who were given pressor
support and/or albumin infusion after onset of sepsis as com-
pared with those who were not. Increased post-onset LOS
and LOS in the ICU were associated with use of PACs. No
associations were found between total LOS and the modali-
ties studied.
Discussion
Overall, we found moderate variation in resource and thera-
peutic modality use among patients with severe sepsis in
academic centers. In general, this variation had little relation-
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Table 3
Adjusted mean hospital charges and post-onset length of stay in patients with severe sepsis
Total charges ($) Post-onset LOS (days)
Site Adjusted mean ± SE Difference ± SE Adjusted mean ± SE Difference ± SE
C1 96,272 ± 6493 Reference 20.1 ± 1.3 Reference
C2 84,514 ± 8221 –11,758 ± 10,537 19.7 ± 1.6 –0.4 ± 2.0
C3 237,898 ± 12,129 141,626 ± 13,758* 20.9 ± 2.3 0.8 ± 2.7
C4 69,429 ± 9562 –26,843 ± 11,561* 22.0 ± 1.8 1.9 ± 2.2
C5 92,778 ± 10,084 –3494 ± 12,001 22.4 ± 1.9 2.3 ± 2.3
C6 100,461 ± 11,565 4189 ± 13,283 18.8 ± 2.2 –1.3 ± 2.6
C7 188,835 ± 10,385 92,563 ± 12,244 * 15.9 ± 2.0 –4.2 ± 2.4
C8 83,043 ± 9484 –13,229 ± 11,516 24.2 ± 1.8 4.1 ± 2.2
r2 = 0.46, P < 0.001 r2 = 0.22, P < 0.001
Adjusted means and r2 were calculated in the generalized linear models, including age, sex, Charlson comorbidity score, discharge diagnosis-
related group weight, organ dysfunction, and service at onset of sepsis. C, center; LOS, length of stay; SE, standard error. *P < 0.05, versus C1.
Table 4
Variation in therapeutic modalities use by center in patients with severe sepsis
Center
Modality C1 C2 C3 C4 C5 C6 C7 C8 All P
PAC (%) 8.7 10.3 25.7 30.6 25.1 24.2 15.5 35.1 19.4 0.001
Ventilator support (%) 11.5 19.6 36.4 34.1 29.3 20.1 12.9 28.3 21.8 0.001
Pressor support after onset (%) 41.8 31.4 53.7 51.8 47.6 42.5 60.4 50.7 45.8 0.001
On albumin within 24 hours after onset (%) 8.2 16.7 13.1 15.4 6.0 13.4 18.1 29.1 14.4 0.001
On hetastarch within 24 hours after onset (%) 0.6 0.5 0 6.3 0 0 0.3 6.8 1.8 0.001
On dextran within 24 hours after onset (%) 2.2 0 0 1.4 0 6.2 0 0.7 1.3 0.001
Antibiotic given within 24 hours after onset (%) 98.5 95.9 87.0 93.9 92.6 93.0 95.5 92.3 94.7 0.001
Data were collected at 28 days or discharge after onset of first sepsis episode. Percentages were calculated using number of admission with
severe sepsis in each center as the denominator; P value for test % variation across sites. C, center; PAC, pulmonary artery catheter.R30
ship to clinical outcomes, although clinical outcomes varied
substantially between the centers. The exception is that, even
adjusting for potential confounders, early antibiotic therapy
was associated with a lower 28-day mortality rate. Increased
use of some of the therapeutic modalities was associated
with greater resource utilization.
Prior studies have shown variability in the use of therapeutic
modalities (including PACs, ventilator, and intravenous
vasoactive and inotropic agents) among ICU patients [21,27]
and different impacts on outcomes and use of hospital
resources associated with these treatments [16–18,28,29].
In general, with the exception of the recent trial demonstrating
benefit of early goal-directed treatment involving oxygenation
(including ventilatory support if necessary) and blood pres-
sure (including intravenous pressors if necessary) [30], few
data are available that demonstrate that these modalities
improve outcomes.
Colloids and crystalloid are equally effective in restoring
tissue perfusion in patients with septic shock [31]. However,
the choice of fluid has considerable cost implications: col-
loids cost more for volume replacement. Largely inappropri-
ate use of colloids was found in a survey of academic health
centers despite guidelines from a US hospital consortium
recommending that colloids be used in hemorrhagic shock
only until blood products become available, and in nonhemor-
rhagic shock only if an initial infusion with crystalloid is insuffi-
cient [32,33]. A recent systematic review of randomized
controlled trials comparing colloids and crystalloid solutions
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Figure 1
Variation in odds ratios (ORs) for therapeutic modalities. C1 was the
reference center. ORs were calculated after adjusting for age, sex,
Charlson comorbidity score and discharge diagnosis-related group
weight, organ dysfunction, and service at onset of sepsis. Albumin, on
albumin within 24 hours after onset; Antibiotic, antibiotic given within
24 hours after onset; CI, confidence interval; PA, pulmonary artery;
Pressor, pressor support; Ventilator, ventilator support.
PA catheter Ventilator Pressor Albumin Antibiotic
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Table 5
Outcomes among patients with severe sepsis
Center
Outcome C1 C2 C3 C4 C5 C6 C7 C8 All P
ARDS (%) 5.5 10.7 13.2 7.3 8.4 6.6 2.8 21.8 9.1 0.001
Renal failure (%) 9.5 15.2 24.5 35.0 32.5 14.8 21.9 20.4 19.7 0.001
Liver failure (%) 11.0 9.6 9.9 27.9 12.7 4.1 5.0 15.7 12.2 0.001
DIC (%) 9.4 14.6 14.0 15.0 10.4 7.2 5.9 5.5 10.3 0.024
Shock (%) 23.9 37.2 45.6 70.0 52.8 42.7 57.8 63.8 45.4 0.001
CNS dysfunction (%) 0.3 15.2 33.8 36.1 35.8 22.4 0.8 37.5 18.9 0.001
Death (%) 19.3 26.0 49.1 31.0 28.3 40.2 36.6 34.0 30.0 0.001
Data were collected at 28 days or discharge after onset of first sepsis episode. Percentages were calculated using number of admission with
severe sepsis in each center as the denominator; P value for test % variation across sites. ARDS, acute respiratory distress syndrome; C, center;
CNS, central nervous system; DIC, disseminated intravascular coagulation.
Figure 2
Variation in odds ratios (ORs) for outcomes. C1 was the reference
center. ORs were calculated after adjusting for age, sex, Charlson
comorbidity score, and discharge diagnosis-related group weight,
organ dysfunction, and service at onset of sepsis. ARDS, acute
respiratory distress syndrome; CI, confidence interval; DIC,
disseminated intravascular coagulation.
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for volume replacement found that resuscitation with colloids
in critically ill patients was actually associated with an
increased risk of mortality [10].
In addition, vasopressors have been recommended to
achieve end-points of hemodynamic, and normal or supranor-
mal oxygen transport variables in sepsis patients who remain
hypotensive despite adequate volume therapy. However, after
reviewing the literature on the use of vasopressors in patients
with sepsis syndrome, Rudis and colleagues [13] found that
catecholamine therapy resulting in increased hemodynamic
and oxygen transport measures did not change the overall
mortality, with the exception of two instances in which epi-
nephrine (adrenaline) and norepinephrine (noradrenaline)
were given alone after volume repletion. The results from a
recent trial of low-dose dopamine in critically ill patients, who
had systemic inflammatory response syndrome and were at
risk for renal failure, did not show benefit in renal protection
and survival from the treatment [34]. However, a very recent
trial of early goal-directed therapy in treatment of sepsis did
demonstrate substantial improvement in outcome [30].
Another technology is monitoring central pressures by PAC,
which is often used in ICUs to assess the effect of pharmaco-
therapy on the cardiac index in patients with septic shock.
This is done even though the efficacy of the PAC has never
been demonstrated convincingly in a large randomized con-
trolled trial. A number of randomized controlled trials have
examined the effectiveness of PACs or PAC-guided strate-
gies in sepsis patients [16–20,35,36] and other specific
patient groups [29,37–43], with conflicting results. A recent
case mix adjusted observational study of a large sample of
ICU patients found that PAC use was associated with
increased risk for mortality and resource use [28].
Mechanical ventilation in patients with ARDS has been
reported to be associated with pneumonia and lung injury
[44–47]. Properly constructed trials are still needed to define
the best use of mechanical ventilation in sepsis, although
early ventilatory support was a component of the recent early
goal-directed intervention by Rivers and coworkers [30].
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Figure 3
Relationship between mortality rate and antibiotic use. This plot
displays the mortality rate versus whether an antibiotic was given
within 24 hours after sepsis onset in the eight centers. The results
were significant for (a) all patients (n=1028) and (b) for the subgroup
(n=924) after excluding those with a ‘do not resuscitate’ order
(n=104).
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Table 6
Comparison of resource use in sepsis patients with and without use of specific modalities
Modalities
Antibiotic
PAC Ventilator support Pressor support On albumin within 24 hours
Resources No Yes r2 No Yes r2 No Yes r2 No Yes r2 No Yes r2
Total charges (× $1000) 114 131 0.35 116 122 0.35 107 146* 0.37 114 141* 0.35 80 117* 0.35
Hospital charges/day 2.8 3.7* 0.14 2.8 4.3* 0.16 2.6 4.6* 0.23 2.9 4.0* 0.14 2.4 2.9* 0.13
(× $1000)
Post-onset LOS (days) 19.8 23.6* 0.22 20.3 21.4 0.22 20.1 21.0 0.21 19.9 23.9 0.22 20.0 20.6 0.21
LOS in ICU (days) 7.1 11.1* 0.41 7.5 9.3 0.40 8.4 13.1* 0.42 7.4 13.0* 0.41 6.3 7.4 0.40
LOS (days) 28.3 32.0 0.26 29.3 28.6 0.25 28.9 29.4 0.25 28.6 32.1 0.25 27.2 29.2 0.25
Mean and r2 values were calculated from the generalized estimating equation regression models adjusting for age, sex, Charlson comorbidity score,
discharge diagnosis-related group weight, organ dysfunction and service at onset of sepsis. Center was a subject-effect variable. *Significant
difference from the group without using modality.R32
Use of some therapeutic modalities does appear correlated
with organizational characteristics. For example, results from
a national ICU survey conducted by Groeger and colleagues
[21] showed that more technologies were used in surgical
units as compared with other units, as well as in larger versus
smaller hospitals, and in university-affiliated facilities. In addi-
tion, a large prospective multicenter study evaluated the dif-
ferences in ICU characteristics and performance among
teaching and nonteaching hospitals [48]. The results of that
study revealed more frequent use of monitoring and therapeu-
tic interventions, and greater resource utilization in teaching
hospital ICUs. Also, a recent report from a large retrospective
database study of ICU patients [27] confirmed that organiza-
tional characteristics of ICUs were associated with variation
in PAC use. In addition, that report indicated that economic
incentives and insurance coverage, as well as clinical vari-
ables, were associated with PAC use. Similarly, much of the
variation in resource use and modality use across centers in
the present study may not be due to patient-related factors,
but rather to organizational factors and physician beliefs.
We did find a number of relationships between modality use
and resource utilization. In particular, there were associations
between LOS in the ICU and use of PACs, pressor support,
and albumin infusion. These may probably be accounted for
in part by the fact that patients with longer LOS in the ICU
were more likely to be treated with supportive technologies.
In general, however, modalities with higher variation profiles
reflect areas of greater disagreement in terms of treatment
decision-making. Such areas may be fertile for additional
investigation.
It is striking that delay in antibiotic therapy was associated
with a higher mortality rate and that some delays were
present in this very ill population. Delays are common in
American medicine [49], even in urgent situations such as
treatment of life-threatening laboratory abnormalities [50].
Although we do not know the causes of delays in antibiotic
initiation, they appeared more common in some institutions
than in others. We speculate that some may have occurred
because of problems related to crowding; for example, emer-
gency rooms or ICUs might have been full, resulting in
delayed transfer, or the clinical importance of changes in vital
signs might not have been recognized. Approaches such as
protocols for early recognition and treatment of severe
sepsis, and facilitation of medication orders that are really
needed urgently may be helpful. Guidelines for the manage-
ment of severe sepsis are probably most applicable for
certain treatment modalities, such as PACs, albumin, dextran,
and hetastarch. Even use of organ failure treatment modalities
such as ventilator support and renal replacement therapies
might be different if such guidelines were developed.
An important underlying issue is why variation occurs [51,52].
It should not be surprising that it is present in this domain,
because the pioneering work of Wennberg [52] identified
variation across a broad array of domains. One of the major
causes of variation is probably physician uncertainty regard-
ing what interventions are truly beneficial, and clinician
beliefs, where training occurred, and regional practices prob-
ably also play roles. Uncertainty may be especially problem-
atic in conditions such as sepsis, in which mortality is high,
and clinicians strongly want to do everything possible. Varia-
tion is likely to diminish as more evidence becomes available
and is brought to the point of care. Analysis of variation can
be very useful for identifying areas of high uncertainty [52].
This study has a number of limitations. We had information
only on hospital charges, rather than hospital costs. We did
not have information on organizational variables such as orga-
nizational setting, staffing, or leadership of practices, and the
study included only academic centers. Also, our data did not
include the indications for use of therapeutic modalities.
In conclusion, significant variations were present in hospital
resource use and patient outcome among sepsis patients
across eight academic medical centers. In general, variation
in therapeutic modality use did not correlate with clinical out-
comes, suggesting that some use of these modalities may be
of limited value, and that further evaluation of these modalities
is warranted. The exception was that delay in giving anti-
biotics to sepsis patients was associated with a higher
28-day mortality rate. Approaches to eliminate these delays
may improve outcomes.
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